台灣臨床試驗主持人資料庫|TPIDB

2016-12-01 - 2018-12-31

Phase II

A Phase IIa, Randomized, Double blinded, Placebo-controlled, Dose-finding Study for Single-dose Administration of TLC599 in Patients with Osteoarthritis (OA) of Knee

Condition/Disease

Osteoarthritis (OA) of Knee
Test Drug

TLC599

Participate Sites
9Sites

Terminated8Sites

張棋楨

Taipei Medical University Hospital

2015-11-16 - 2022-01-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

Condition/Disease

Diabetic kidney disease
Test Drug

BAY 94-8862/ Finerenone

Participate Sites
9Sites

Terminated9Sites

吳麥斯

Taipei Medical University Hospital

Division of Nephrology

唐德成

Taipei Veterans General Hospital

Division of Nephrology

2015-11-26 - 2022-12-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

Condition/Disease

Diabetic kidney disease
Test Drug

BAY 94-8862/ Finerenone

Participate Sites
9Sites

Terminated9Sites

吳麥斯

Taipei Medical University Hospital

Division of Nephrology

唐德成

Taipei Veterans General Hospital

Division of Nephrology

2017-07-01 - 2018-09-30

Phase II

A Phase 2, Double-blind, Randomized Controlled Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult Volunteers

Condition/Disease

Influenza Virus Vaccine
Test Drug

AD07030

Participate Sites
5Sites

Terminated5Sites

劉明哲

Taipei Medical University Hospital

Division of Urology

李文生

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

2015-04-15 - 2020-09-30

Phase I

An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy with Escalating Doses of OBI-833/OBI-821 (Globo H-CRM197/Adjuvant) in Subjects with Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer

Condition/Disease

Metastatic Gastric, Lung, Colorectal or Breast Cancer
Test Drug

OBI-833 (Globo H-CRM197)/OBI-821

Participate Sites
4Sites

Recruiting4Sites

李凱靈

Taipei Medical University Hospital

Division of Hematology & Oncology

Search Result

List